AbbVie and DISCO Pharmaceuticals Sign Oncology Drug Discovery Deal Worth Up to $2.54 Billion

20 November 2026 | Friday | News

DISCO Pharmaceuticals will receive $40 million upfront and could earn up to $2.5 billion in additional payments under a collaboration to develop AND-gated bispecific therapies for solid tumours. The partnership will use DISCO’s DISCOtech platform to identify tumour-selective target pairs, aiming to improve treatment precision while limiting damage to healthy tissue.
Image Source: Public Domain

Image Source: Public Domain

DISCO Pharmaceuticals (“DISCO”) announced a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.

Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.

“The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors,” said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech® platform’s unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window.”

“We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs,” added Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close